Humacyte
Global leader in engineering regenerative medicine products to save and improve patient lives.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $50.0m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | 845 % | 155 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | (353 %) | (61 %) | 18 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Humacyte, Inc. is a biotechnology startup based in Durham, North Carolina, that specializes in the development and manufacture of bioengineered human tissues and organs. These products are designed to be universally implantable, aiming to revolutionize medical treatments and improve patient lives. The company's flagship product is the Humacyte Human Acellular Vessel (HAV), a regenerative vascular conduit. This product is currently undergoing various stages of clinical trials for multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease.
Humacyte's business model revolves around the development of these bioengineered products, which are then sold to healthcare providers. The company operates in the biotechnology and healthcare markets, serving clients such as hospitals, clinics, and other medical facilities. Its revenue is generated through the sale of these bioengineered tissues and organs.
The company also believes its platform technology has the potential to create solutions for complex organ diseases. This includes the development of bioengineered replacement tissues and organs for procedures such as coronary artery bypass grafts, pediatric heart surgery, and the treatment of Type 1 diabetes.
Founded in 2004 by Dr. Laura Niklason, a world leader in tissue engineering, along with Drs. Juliana Blum and Shannon Dahl, Humacyte is listed on the Nasdaq under the ticker symbol HUMA.
Keywords: Biotechnology, Bioengineered Tissues, Bioengineered Organs, Healthcare, Clinical Trials, Vascular Applications, Hemodialysis, Peripheral Arterial Disease, Organ Disease, Nasdaq: HUMA.